Spinal Muscular Atrophy Sma Global Api Manufacturers Marketed And Phase Iii Drugs Landscape

"Spinal Muscular Atrophy (SMA) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report by DelveInsight offers comprehensive insights on marketed and Phase III products for Spinal Muscular Atrophy (SMA). The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2023. It further provides the marketed products API manufacturer details for United States, Europe, China, and India. The report also covers the emerging Phase III pipeline assets for Spinal Muscular Atrophy (SMA) including their detailed product profiles.


Additionally, the report also highlights the future competitive landscape for Spinal Muscular Atrophy (SMA) therapeutics. Depending on information availability comprehensive coverage of the following for Spinal Muscular Atrophy (SMA) marketed products for Spinal Muscular Atrophy (SMA) descriptive marketed product profiles for Spinal Muscular Atrophy (SMA) including (but not limited to) drug description, regulatory milestones, product development and R&D activities encompassing clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also provided are the historical and forecasted global sales till 2023 for each product.


Global API Manufacturers of marketed products for Spinal Muscular Atrophy (SMA) coverage of API manufacturers for Spinal Muscular Atrophy (SMA) marketed products spanning across United States, Europe, China and India. The manufacturers details include manufacturers name along with their location Emerging Phase III products for Spinal Muscular Atrophy (SMA) descriptive Phase III product profiles for Spinal Muscular Atrophy (SMA) including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also their forecasted global sales are provided till 2023.

Report Methodology 

The report provides insights into: 

  • Detailed description of the indication including causes, symptoms, pathophysiology, diagnosis and treatment
  • Comparative analysis of the marketed and emerging products 
  • Detailed profiles for the marketed therapies available including mechanism of action, dosage and administration regulatory milestones, other development activities 
  • Global sales of the marketed therapies from 2012-2023 is covered in the report
  • Global API Manufacturers for marketed therapies are provided across United States, Europe, China and India
  • List of emerging therapies with product name, company, stage of development, indication, route of administration and molecule type is also provided  

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.


Spinal Muscular Atrophy (SMA) Analytical Perspective by DelveInsight

  • In-depth Spinal Muscular Atrophy (SMA) Commercial Assessment of Marketed Products 

This report provides an in-depth commercial assessment of marketed products, which comprises the details of collaborations, licensing, acquisition - deal value trends, patent and global sales.


  • Spinal Muscular Atrophy (SMA) Clinical Assessment of Emerging Products

The report comprises of comparative clinical assessment of products by development stage, route of administration and molecule type across this indication.


Scope of the report

  • The Spinal Muscular Atrophy (SMA) report provides a comprehensive understanding of Spinal Muscular Atrophy (SMA) marketed and emerging (Phase III) products
  • Access to API manufacturers details for Spinal Muscular Atrophy (SMA) marketed drugs to devise API procurement strategy for generic development
  • Plan developmental timelines around marketed drug patents for the major markets- US and EU
  • Understand current and future growth of marketed Spinal Muscular Atrophy (SMA) therapeutics through their historical and forecasted sales
  • Identify and analyze future sales trends of emerging Phase III Spinal Muscular Atrophy (SMA) therapeutics through their forecasted sales
  • Identify the products attributes and use it for target finding, drug repurposing, and precision medicine
  • Identify and plan ahead for prospective emerging players and their products for Spinal Muscular Atrophy (SMA)


Report highlights

  • In the coming years, the Spinal Muscular Atrophy (SMA) market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Spinal Muscular Atrophy (SMA) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • There are many companies involved in developing therapies for Spinal Muscular Atrophy (SMA). Launch of emerging therapies of Spinal Muscular Atrophy (SMA) will significantly impact the market.
  • A better understanding of target mechanism will also contribute to the development of novel therapeutics for Spinal Muscular Atrophy (SMA).
  • Our in-depth analysis of the marketed and late-stage pipeline assets comparative analysis of the products. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.


Key Questions

  • What are the current treatment options available based on the Spinal Muscular Atrophy (SMA)?
  • How many companies are developing therapies for Spinal Muscular Atrophy (SMA)?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for Spinal Muscular Atrophy (SMA) to treat disease condition?
  • How many emerging therapies are in late stage of development for Spinal Muscular Atrophy (SMA)?
  • What is the trend of historical and forecasted sales of the marketed products from the period 2012-2023?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spinal Muscular Atrophy (SMA) therapies? 
  • Which are the API manufacturers across United States, Europe, China and India for the marketed therapies?
  • How many patents are granted to the marketed therapies of Spinal Muscular Atrophy (SMA)?
  • How late-stage emerging therapies are distinguished on the basis of their mechanism of action, route of administration and molecule type? 

1. Report Introduction

2. Spinal Muscular Atrophy (SMA)

2.1. Spinal Muscular Atrophy (SMA) Symptoms

2.2. Spinal Muscular Atrophy (SMA) Causes  

2.3. Spinal Muscular Atrophy (SMA) Types 

2.4. Spinal Muscular Atrophy (SMA) Risk Factors / Complications

2.5. Spinal Muscular Atrophy (SMA) Pathophysiology

2.6. Spinal Muscular Atrophy (SMA) Diagnosis

2.7. Spinal Muscular Atrophy (SMA) Treatment

3. Comparative Analysis of Marketed and Emerging Products

3.1. Marketed Products

3.1.1. Drug A: Company 

3.1.1.1. Product Description

3.1.1.2. Regulatory Milestones

3.1.1.3. Product Development Activities

3.1.1.3.1. General Description Table

3.1.1.4. Global Sales

3.1.1.5. Global API Manufacturers for Drug A

3.1.1.5.1. United States

3.1.1.5.2. Europe

3.1.1.5.3. China 

3.1.1.5.4. India

3.1.2. Drug B: Company

3.1.2.1. Product Description

3.1.2.2. Regulatory Milestones

3.1.2.3. Product Development Activities

3.1.2.3.1. General Description Table

3.1.2.4. Global Sales

3.1.2.5. Global API Manufacturers for Drug B

3.1.2.5.1. United States

3.1.2.5.2. Europe

3.1.2.5.3. China 

3.1.2.5.4. India

Complete details in the report

3.1.3. Emerging Therapies - Late Phase 

3.1.3.1. List of Phase III drugs for Spinal Muscular Atrophy (SMA)

4. Appendix

5. Report Methodology

5.1. Secondary Research

5.2. Expert Panel Validation

Table 1  : List of Marketed and Emerging Products

Table 2 : Drug A Annual Global Sales from 2012-2023 (in USD million)

Table 3 : API Manufacturers for Drug A Region wise

Table 4 : API Manufacturers for Drug A for the United States

Table 5 : API Manufacturers for Drug A for Europe

Table 6 :/ API Manufacturers for Drug A for India

Table 7 : API Manufacturers for Drug A for China

Table 8 : Drug B Annual Global Sales from 2012-2023 (in USD million)

Table 9 : API Manufacturers for Drug B Region wise

Table 10 : API Manufacturers for Drug B for the United States

Table 11 : API Manufacturers for Drug B for Europe

Table 12 : API Manufacturers for Drug B for India

Table 13 : API Manufacturers for Drug B for China

Table 14 : Drug C Annual Global Sales from 2014-2023 (in USD million)

Table 15 : API Manufacturers for Drug C Region wise

Table 16 : API Manufacturers for Drug C for the United States

Table 17 : API Manufacturers for Drug C for Europe

Table 18 : API Manufacturers for Drug C for India

Table 19 : API Manufacturers for Drug C for China

Table 20 : Drug D, Annual Global Sales from 2013-2023 (in USD million)

Table 21 : API Manufacturers for Drug D Region wise

Table 22 : API Manufacturers for Drug D for the United States

Table 23 : API Manufacturers for Drug D for Europe

Table 24 : API Manufacturers for Drug D for India

Table 25 : API Manufacturers for Drug D for China

Table 26 : Drug E Annual Global Sales from 2014-2023 (in USD million)

Table 27 : API Manufacturers for Drug E Region wise

Table 28 : API Manufacturers for Drug E for the United States

Table 29 : API Manufacturers for Drug E for Europe

Table 30 : API Manufacturers for Drug E for India

Table 31 : API Manufacturers for Drug E for China

Table 32 : List of Phase III drugs for Spinal Muscular Atrophy (SMA)


Figure 1 : Comparative Analysis of Marketed and Emerging Products

Figure 2 : Drug A, Annual Global Sales from 2012-2023 (in USD million)

Figure 3 : API Manufacturers for Drug A Region wise

Figure 4 : Drug B, Annual Global Sales from 2012-2023 (in USD million)

Figure 5 : API Manufacturers for Drug B Region wise

Figure 6 : Drug C, Annual Global Sales from 2014-2023 (in USD million)

Figure 7 : API Manufacturers for Drug C Region wise

Figure 8 : Drug D, Annual Global Sales from 2011-2023 (in USD million)

Figure 9 : API Manufacturers for Drug D Region wise

Figure 10 : Drug E, Annual Global Sales from 2014-2023 (in USD million)

Figure 11 : API Manufacturers for Drug E Region wise

  • Tags:
  • Spinal Muscular Atrophy (SMA)
  • Spinal Muscular Atrophy (SMA) Mark...
  • Spinal Muscular Atrophy (SMA) Marke...
  • Spinal Muscular Atrophy (SMA) Pipe...
  • Spinal Muscular Atrophy (SMA) API...
  • Spinal Muscular Atrophy (SMA) DMF
  • Spinal Muscular Atrophy (SMA) Activ...
  • Spinal Muscular Atrophy (SMA) Certi...
  • Spinal Muscular Atrophy (SMA) Paten...
  • Spinal Muscular Atrophy (SMA) Paten...
  • Spinal Muscular Atrophy (SMA) Phase...
  • Spinal Muscular Atrophy (SMA) API M...
  • Spinal Muscular Atrophy (SMA) Globa...
  • Spinal Muscular Atrophy (SMA) Globa...
  • Spinal Muscular Atrophy (SMA) Marke...
  • Spinal Muscular Atrophy (SMA) Comp...

Forward to Friend

Need A Quote